{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T14:01:36Z","timestamp":1782828096290,"version":"3.54.5"},"reference-count":28,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":33,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alz &amp; Dem Diag Ass &amp; Dis Mo"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>Establishing interchangeability between blood biomarkers and amyloid\u2010positron emission tomography (PET) could help identify patients who would benefit from novel amyloid\u2010targeting therapies for Alzheimer's disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>\n                      Adult participants from the Global Alzheimer's Platform Foundation's Bio\u2010Hermes study with clinical diagnosis of mild cognitive impairment\/mild dementia and available amyloid\u2010PET evaluations and A\u03b242\/40\u2010based PrecivityAD\n                      <jats:sup>\u00ae<\/jats:sup>\n                      (by C2N Diagnostics) and\/or phosphorylated tau at threonine 217 (p\u2010Tau217 (research use Meso Scale Discovery, Lilly) were included. Interchangeability between plasma\u2010based tests (per\n                      <jats:italic>pre\u2010established<\/jats:italic>\n                      thresholds) and amyloid\u2010PET stratifications was evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      PrecivityAD (\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u00a0537) and p\u2010Tau217 (\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u00a0531) plasma\u2010based tests had high agreement with florbetapir\u2010PET (overall percent agreement: 80.7% and 90.1%, respectively) and accurately selected patients identified as florbetapir\u2010PET\u2010positive (positive predictive value: 86.0% and 88.0%, respectively). Further, they were non\u2010inferior to quantitative florbetapir\u2010PET (at 37 Centiloids) for identifying positive florbetapir\u2010PET visual reads.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION<\/jats:title>\n                    <jats:p>Results support the hypothesis that blood biomarkers may be interchangeable with amyloid\u2010PET criteria for selecting patients who may benefit from treatment with novel amyloid\u2010targeting therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Highlights<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Interchangeability of plasma\u2010based tests and amyloid\u2010PET stratifications was demonstrated.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Non\u2010inferiority of plasma\u2010based biomarkers to amyloid\u2010PET for identifying patients with AD pathology was observed.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>High agreement between plasma\u2010based test stratification and florbetapir\u2010PET expert visual read was observed.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/dad2.70196","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:38:08Z","timestamp":1770107888000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Interchangeability of blood\u2010based biomarkers and PET to identify Alzheimer's disease pathology"],"prefix":"10.1002","volume":"18","author":[{"given":"Jian","family":"Wang","sequence":"first","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel B.","family":"Braunstein","sequence":"additional","affiliation":[{"name":"C2N Diagnostics  St. Louis Missouri USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Wolz","sequence":"additional","affiliation":[{"name":"Imperial College London  London UK"},{"name":"IXICO  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Harper","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tricia","family":"Locascio","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly E.","family":"McPherson","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Mohs","sequence":"additional","affiliation":[{"name":"Global Alzheimer's Platform Foundation  Washington District of Columbia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Pontecorvo","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4805-5193","authenticated-orcid":false,"given":"Samantha C.","family":"Burnham","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010021\u201001382\u2010x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(21)00066\u20101"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311\u2010021\u201001146\u2010y"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph14020110"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43587\u2010022\u201000269\u2010x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474\u20104422(16)00070\u20103"},{"key":"e_1_2_8_11_1","unstructured":"Neto\u2010RosaP ZimmerE.Chapter 11: Spinal Fluid. World Alzheimer Report 2021 by Alzheimer's Disease International. Accessed May 24 2024.https:\/\/www.alzint.org\/u\/World\u2010Alzheimer\u2010Report\u20102021\u2010Chapter\u201011.pdf"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13722"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.8392"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2021.05.011"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51763"},{"key":"e_1_2_8_16_1","unstructured":"U.S. Food & Drug Administration.Amyvid\u00ae D (Florbetapir F 18 Injection) Full Prescribing Information. Accessed May 24 2024.https:\/\/pi.lilly.com\/us\/amyvid\u2010uspi.pdf"},{"key":"e_1_2_8_17_1","unstructured":"European Medicines Agency.Summary of Product Characteristics. Amyvid INN\u2010florbetapir [18F]. Accessed May 24 2024.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/amyvid\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000001693"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.06.1353"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/19466315.2016.1202859"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43587\u2010023\u201000471\u20105"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12134"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010020\u20100755\u20101"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa286"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.13855"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14315"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awx057"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.19919"}],"container-title":["Alzheimer's &amp; Dementia: Diagnosis, Assessment &amp; Disease Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dad2.70196","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dad2.70196","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dad2.70196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:12:23Z","timestamp":1781089943000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/dad2.70196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/dad2.70196"],"URL":"https:\/\/doi.org\/10.1002\/dad2.70196","archive":["Portico"],"relation":{},"ISSN":["2352-8729","2352-8729"],"issn-type":[{"value":"2352-8729","type":"print"},{"value":"2352-8729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-03-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70196"}}